| Literature DB >> 23675082 |
Nahed El-Enany1, Fathalla Belal, Mohamed Rizk.
Abstract
A simple spectrophotometric method was developed for the determination of captopril (CPL) in pharmaceutical preparations. The method is based on coupling captopril with 2,6-dichloroquinone-4-chlorimide (DCQ) in dimethylsulphoxide. The yellow reaction product was measured at 443 nm. The absorbance-concentration plot was rectilinear over the range of 10-50 μg/mL with minimum detection limit (LOD) of 0.66 μg/mL and a quantification limit (LOQ) of 2.0 μg/mL. The different experimental parameters affecting the development and stability of the color were carefully studied and optimized. The proposed method was successfully applied to the analysis of commercial tablets and the results were in good agreement with those obtained using official and reference spectrophotometric methods. Hydrochlorothiazide which is frequently co-formulated with CPL did not interfere with the assay. A proposal of the reaction pathway was presented.Entities:
Keywords: 2,6-dichloroquinone-4-chlorimide (DCQ); captopril; dosage forms; spectrophotometry
Year: 2008 PMID: 23675082 PMCID: PMC3614690
Source DB: PubMed Journal: Int J Biomed Sci ISSN: 1550-9702
Figure 1Structural formula of captopril.
Effect of pH on the formation, intensity and stability of the reaction product of captopril (30 μg/mL)
| Buffer (pH) | λ max. (nm) | Absorbance | Stability |
|---|---|---|---|
| No buffer | 443 | 0.355 | Stable |
| Acetate buffer ( | 415 | 0.23 | Stable |
| Borate buffer ( | 439 | 0.277 | Stable |
| 0.1 M NaHCO3 ( | 443 | 0.210 | Stable |
| Borate buffer ( | 448 | 0.289 | Not stable |
| Ammonium buffer ( | 440 | 0.301 | Not stable |
Effect of different solvents on the color formation and intensity of the reaction product of captopril (30 μg/mL)
| Solvent | Color development | λ max (nm) | Absorbance |
|---|---|---|---|
| Acetonitrile | Very slow | 435 | 0.056 |
| Acetone | Slow | 437 | 0.195 |
| Methanol | Slow | 434 | 0.182 |
| Ethanol | Slow | 437 | 0.222 |
| Water | Immediate | 411 | 0.168 |
| Dimethylsulphoxide | Immediate | 443 | 0.355 |
Effect of surfactants and sensitizers on the absorbance of the reaction product of captopril (30 μg/mL) with DCQ
| Substance | Concentration, μg/mL | Absorbance |
|---|---|---|
| No surfactant | – | 0.355 |
| Cetrimide | 2.5 | 0.302 |
| Sodium lauryl sulfate | 2.5 | 0.351 |
| Gelatin | 2.5 | 0.347 |
| Cetrimide | 7.5 | 0.307 |
| Sodium lauryl sulfate | 7.5 | 0.416 |
| Gelatin | 7.5 | 0.327 |
| Cetrimide | 15 | 0.325 |
| Sodium lauryl sulfate | 15 | 0.442 |
| Gelatin | 15 | 0.337 |
| No sensitizer | – | 0.355 |
| Quinine | 5 | 0.348 |
| Fluorescein | 5 | 0.385 |
| Rhodamine-B | 5 | 0.404 |
Performance data of the proposed method
| Parameter | Proposed method |
|---|---|
| Concentration range, μg/mL | 10-50 |
| Limit of detection (LOD) (μg/mL) | 0.66 |
| Limit of Quantification (LOQ) (μg/mL) | 2.0 |
| Correlation coefficient (r). | 0.9997 |
| Slope | 0.012 |
| Intercept | 1.8 × 10-3 |
| S y/x | 5.45 × 10-3 |
| Sa | 2.33 × 10-3 |
| Sb | 1.72 × 10-4 |
| %Error | 0.52 |
| Applications | Tablets |
Sy/x, standard deviation of the residuals; Sa, standard deviation of the intercept of regression line; Sb, standard deviation of the slope of regression line; % Error, RSD% / √ n.
Figure 2Absorption spectra of: A, the reaction product of captopril (50 μg/mL) and DCQ; B, reagent blank.
Figure 3Effect of volume of DMSO (mL) on the absorbance value of the reaction product (captopril 30 μg/mL) at 443 nm.
Figure 4Effect of volume of DCQ (0. 25%) (mL) on the absorbance value of the reaction product (captopril 30 μg/mL) at 443 nm.
Application of the proposed method and official methods for the determination of captopril in pure form
| Parameters | Proposed method | Official method ( |
|---|---|---|
| No. of experiments | 5 | 3 |
| Mean found, % ± SD | 100.15 ± 1.17 | 99.89 ± 0.78 |
| RSD, % | 1.17 | 0.78 |
| Variance | 1.37 | 0.61 |
| Student’s t-value | 0.34 (2.45) | - |
| Variance ratio F-test | 2.25 (6.94) | - |
Values in parentheses are the tabulated values of t and F respectively at p = 0.05 (35).
Application of the proposed method to the determination of captopril in dosage forms
| Preparation | % Recovery Proposed method | % Recovery Reference method ( |
|---|---|---|
| 1-Capoten tablets | 98.73 | 99.64 |
| 100.83 | 100.54 | |
| 99.88 | 101.30 | |
| 98.40 | - | |
| 99.15 | - | |
| X- ± SD. | 99.40 ± 0.97 | 100.49 ± 0.83 |
| t-value. | 1.61(2.45) | - |
| F-value | 1.36 (6.94) | - |
| 2-Capozide tablets | 100.32 | 99.50 |
| 100.41 | 101.05 | |
| 100.28 | 100.88 | |
| 98.84 | - | |
| 99.83 | - | |
| X- ± SD. | 99.94 ± 0.65 | 100.48 ± 0.85 |
| t-value. | 1.03 (2.45) | - |
| F-value. | 1.71 (6.94) | - |
product of Squibb Egypt Co. Giza, Egypt (Batch # B10401204);
product of Squibb Egypt Co. Giza, Egypt (Batch # E11477).
Values in parenthesis are the tabulated; t and F values respectively at p = 0.05 (35).
Figure 5Limiting logarithmic plots for the molar ratio. (A) Log A vs. Log (DQ); (B) Log A vs. log (captopril).
Figure 6Proposal of the reaction pathway between DCQ and captopril.